Compare LGIH & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | NKTR |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2013 | 1996 |
| Metric | LGIH | NKTR |
|---|---|---|
| Price | $42.40 | $37.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $133.08 |
| AVG Volume (30 Days) | 340.8K | ★ 1.4M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,705,504,000.00 | $307,711,000.00 |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $11.62 | $30.00 |
| P/E Ratio | $34.07 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $33.55 | $33.40 |
| 52 Week High | $66.25 | $109.00 |
| Indicator | LGIH | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 29.26 |
| Support Level | $39.35 | $34.45 |
| Resistance Level | $51.77 | $39.59 |
| Average True Range (ATR) | 2.26 | 1.98 |
| MACD | 0.06 | 0.67 |
| Stochastic Oscillator | 42.96 | 23.79 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.